Alexion Reports First Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharma (ALXN) Tops Q1 EPS by 20c, Raises FY Guidance
April 25, 2019 6:32 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q1 EPS of $2.39, $0.20 better than the analyst estimate of $2.19. Revenue for the quarter came in at $1.14 billion versus the consensus estimate of $1.13 billion.
GUIDANCE:
Alexion Pharma sees FY2019 EPS of $9.25-$9.45, versus the consensus of... More
